Safety of Flunotinib Maleate Tablets for the Treatment of Patients With Myeloproliferative Neoplasms Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Phase I/II Trial

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Sep 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Flonoltinib maleate (Primary)
Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera; Splenomegaly
Focus Pharmacokinetics
Sponsors Chengdu Zenitar Biomedical Technology

16 Jan 2023 Planned End Date changed from 28 Feb 2023 to 28 Dec 2023.
16 Jan 2023 Planned primary completion date changed from 29 Dec 2022 to 29 Nov 2023.
09 Mar 2022 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com